ICU Medical Reports $551.7 Million Revenue in Q2 2026, Net Income Declines

ICU Medical, Inc. reported a total revenue of $551.7 million for the second quarter of 2026, a slight increase from $548.9 million in the same period last year. For the first half of 2026, revenues totaled $1.08 billion, down from $1.15 billion in the first half of 2025. The company’s gross profit for the second quarter was $235.1 million, yielding a gross margin of 42.6%, compared to 38% in the prior year. The increase in gross margin was attributed to tariff refunds and the sale of a lower-margin IV Solutions business, which contributed to a more favorable product mix.

In terms of profitability, ICU Medical reported a net income of $19.1 million for the second quarter, down from $35.3 million in the same quarter of 2025. The decline was influenced by a significant gain on the sale of business recorded in the previous year. The company’s diluted earnings per share for the second quarter were $0.76, compared to $1.43 in the prior year. The decrease in net income was also impacted by restructuring and integration expenses, which rose to $21.3 million in the second quarter, up from $16.2 million in the same period last year.

Strategically, ICU Medical has been focusing on integrating its acquisition of Smiths Medical, which has resulted in increased restructuring costs. The company incurred $8.3 million in strategic transaction and integration expenses during the second quarter, reflecting ongoing efforts to streamline operations post-acquisition. Additionally, ICU Medical has entered into a definitive agreement to divest certain assets, which is expected to be immaterial to its financial position.

Operationally, the company reported a decrease in its inventory levels, which fell to $607.4 million from $615.9 million at the end of 2025. The reduction in inventory was primarily due to strong sales volumes and production delays. ICU Medical's cash and cash equivalents stood at $298.3 million as of June 30, 2026, down from $308 million at the end of 2025, reflecting principal payments on long-term debt and tax withholding payments related to employee equity awards.

Looking ahead, ICU Medical anticipates continued challenges from global economic conditions, including inflation and supply chain disruptions. The company expects to maintain its focus on operational efficiencies and strategic growth initiatives while navigating these external pressures. The management remains optimistic about future revenue growth driven by its product portfolio and market demand, despite the uncertainties in the macroeconomic environment.